InsiderTrades.com logo
New Year, New Opportunity! 2 AI Stocks Under $10 Ready to Soar
From Darwin   |   Ad
As we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.
👉 Click here to access your FREE report now!
David Zaccardelli net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

David Zaccardelli Biography and Net Worth

CEO of Verona Pharma
From December 2018 until its acquisition by Swedish Orphan Biovitrum for up to $915 million in November 2019, Dr Zaccardelli served as President and CEO of Dova Pharmaceuticals, a US company developing therapeutics for rare diseases. Previously, he was Acting CEO of Cempra, from December 2016 until the company’s merger with Melinta Therapeutics in November 2017. From 2004 until 2016, Dr Zaccardelli served in several senior management roles at United Therapeutics Corporation, including Chief Operating Officer, Chief Manufacturing Officer and Executive Vice President, Pharmaceutical Development and Operations. Prior to United Therapeutics, he founded and led a start-up company focused on contract research positions and held a variety of clinical research positions at Burroughs Wellcome & Co, Glaxo Wellcome, and Bausch & Lomb Pharmaceutical. Dr Zaccardelli received a Pharm.D. from the University of Michigan.

What is David Zaccardelli's net worth?

The estimated net worth of David Zaccardelli is at least $590.61 million as of November 11th, 2024. Dr. Zaccardelli owns 15,202,352 shares of Verona Pharma stock worth more than $590,611,375 as of November 20th. This net worth approximation does not reflect any other investments that Dr. Zaccardelli may own. Additionally, Dr. Zaccardelli receives an annual salary of $1,270,000.00 as CEO at Verona Pharma. Learn More about David Zaccardelli's net worth.

How old is David Zaccardelli?

Dr. Zaccardelli is currently 60 years old. There are 4 older executives and no younger executives at Verona Pharma. Learn More on David Zaccardelli's age.

What is David Zaccardelli's salary?

As the CEO of Verona Pharma plc, Dr. Zaccardelli earns $1,270,000.00 per year. Learn More on David Zaccardelli's salary.

How do I contact David Zaccardelli?

The corporate mailing address for Dr. Zaccardelli and other Verona Pharma executives is 3 MORE LONDON RIVERSIDE, LONDON X0, SE1 2RE. Verona Pharma can also be reached via phone at 011-44-0-2032834200 and via email at [email protected]. Learn More on David Zaccardelli's contact information.

Has David Zaccardelli been buying or selling shares of Verona Pharma?

In the last ninety days, David Zaccardelli has sold $2,212,086.88 of Verona Pharma stock. Most recently, David Zaccardelli sold 2,400 shares of the business's stock in a transaction on Monday, November 11th. The shares were sold at an average price of $5.00, for a transaction totalling $12,000.00. Following the completion of the sale, the chief executive officer now directly owns 15,202,352 shares of the company's stock, valued at $76,011,760. Learn More on David Zaccardelli's trading history.

Who are Verona Pharma's active insiders?

Verona Pharma's insider roster includes Lisa Deschamps (Director), David Ebsworth (Director), Martin Edwards (Director), Patrick Finn (Insider), Mark Hahn (CFO), Claire Poll (General Counsel), Kathleen Rickard (Insider), Anders Ullman (Director), and David Zaccardelli (CEO). Learn More on Verona Pharma's active insiders.

Are insiders buying or selling shares of Verona Pharma?

In the last year, Verona Pharma insiders bought shares 2 times. They purchased a total of 73,096 shares worth more than $251,002.24. In the last year, insiders at the sold shares 13 times. They sold a total of 1,178,192 shares worth more than $5,075,998.08. The most recent insider tranaction occured on November, 11th when CEO David Zaccardelli sold 2,400 shares worth more than $12,000.00. Insiders at Verona Pharma own 4.8% of the company. Learn More about insider trades at Verona Pharma.

Information on this page was last updated on 11/11/2024.

David Zaccardelli Insider Trading History at Verona Pharma

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/11/2024Sell2,400$5.00$12,000.0015,202,352View SEC Filing Icon  
11/4/2024Sell94,144$4.39$413,292.1615,204,752View SEC Filing Icon  
11/1/2024Sell46,888$4.38$205,369.4415,298,896View SEC Filing Icon  
10/25/2024Sell4,800$4.38$21,024.0014,591,736View SEC Filing Icon  
10/23/2024Sell16$4.38$70.0814,736,536View SEC Filing Icon  
10/21/2024Sell110,456$4.38$483,797.2814,894,464View SEC Filing Icon  
10/18/2024Sell245,784$4.38$1,076,533.9215,004,920View SEC Filing Icon  
8/7/2023Sell8,616$2.47$21,281.5216,431,800View SEC Filing Icon  
8/4/2023Sell150,000$2.50$375,000.0016,440,416View SEC Filing Icon  
8/2/2023Sell73,704$2.59$190,893.3616,707,688View SEC Filing Icon  
5/1/2023Sell455,536$2.58$1,175,282.8816,887,336View SEC Filing Icon  
2/1/2023Sell432,928$2.56$1,108,295.6817,342,872View SEC Filing Icon  
12/20/2022Sell600,000$2.12$1,272,000.0017,775,800View SEC Filing Icon  
8/9/2022Sell600,000$1.75$1,050,000.0015,263,560View SEC Filing Icon  
8/1/2022Sell32,904$0.70$23,032.8015,863,560View SEC Filing Icon  
5/3/2022Sell32,904$0.50$16,452.0016,351,328View SEC Filing Icon  
2/3/2022Sell52,056$0.73$38,000.88View SEC Filing Icon  
11/2/2021Sell52,056$0.64$33,315.84View SEC Filing Icon  
8/3/2021Sell16,000$0.76$12,160.00View SEC Filing Icon  
3/1/2021Sell43,392$1.14$49,466.88View SEC Filing Icon  
See Full Table

David Zaccardelli Buying and Selling Activity at Verona Pharma

This chart shows David Zaccardelli's buying and selling at Verona Pharma by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Verona Pharma Company Overview

Verona Pharma logo
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom.
Read More

Today's Range

Now: $38.85
Low: $37.61
High: $39.33

50 Day Range

MA: $33.12
Low: $27.64
High: $39.87

2 Week Range

Now: $38.85
Low: $11.39
High: $40.13

Volume

1,155,655 shs

Average Volume

934,647 shs

Market Capitalization

$3.11 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.42
“This Changes Everything” - Trump Hands Millions Massive IRS Gift
From Colonial Metals   |   Ad
Now it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as we wait for Trump's agenda to kick in…
>> YES! Send Me My FREE Gold Guide!